



Research agreement for pre-clinical peptide analysis at Medical University of Vienna

- *Research to support IND and Phase II trial*

Melbourne, 8 September 2014: Imugene Limited (ASX: IMU) has signed an agreement with Professor Ursula Wiedermann and her research group at the Medical University of Vienna to conduct preclinical immunology experiments in preparation for the 2015 clinical trials of HER-Vaxx.

The research will focus on peptides and peptide-incorporated influenza virosomes to be used in the upcoming HER-Vaxx Phase II clinical trial. Professor Wiedermann is head of the Institute of Specific Prophylaxis and Tropical Medicine at the Medical University of Vienna and her research group within the department will carry out the work.

Professor Wiedermann is a member of the Imugene Scientific Advisory Board and was the principal investigator for the preclinical development of HER-Vaxx. She has led the design of the HER-Vaxx Phase II study for gastric cancer due to commence in 2015.

“We expect this high quality research and the results subsequently generated by Professor Wiedermann and her team, to support our Phase II trial design and IND application to the US FDA,” said Imugene CEO Charles Walker.

Professor Wiedermann is a Professor in Vaccinology who has been published in over 100 peer-reviewed publications and is a renowned presenter at medical innovation conferences worldwide. As well as the preclinical development of HER-Vaxx, she performed the Phase I clinical trial in metastatic breast cancer patients with Professor Christoph Zielinski.

-ends

Contact :

Charles Walker, Chief Executive Officer - +61 450 446 990 (Australia) Paul Hopper, Executive Chairman - +1 858 334 5820 (US) or +61 406 671 515 (Australia)

Media contact:

Rudi Michelson, Monsoon Communications – +61 3 9620 3333 / rudim@monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immune-oncology company developing clinical immunotherapies to advance cancer care. The Company’s lead product is HER-Vaxx, a proprietary immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com